NVCR

NovoCure Ltd NVCR

NasdaqSmall CapHealthcare
InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro quality score

Rank #2,231 of 2,925

Why it scores 37Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$183.58M

Quarter to Jun 30

Net income

$-15.66M

Quarter to Jun 30

Free cash flow

$1.22M

Quarter to Jun 30

Operating margin

-5.8%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$1.57B total
FMR LLC
$263.20M+1.8%
BlackRock, Inc.
$203.22M+1.7%
Soleus Capital Management, L.P.
$150.19M-5.5%
VANGUARD PORTFOLIO MANAGEMENT LLC
$95.03M+0.3%
VANGUARD CAPITAL MANAGEMENT LLC
$74.29M+4.7%
MORGAN STANLEY
$68.51M-0.4%
STATE STREET CORP
$43.43M+11.9%
GEODE CAPITAL MANAGEMENT, LLC
$42.40M+11.4%
WELLS FARGO & COMPANY/MN
$38.30M-14.3%
Quantinno Capital Management LP
$33.69M-10.6%
RENAISSANCE TECHNOLOGIES LLC
$29.57M+25.8%
JPMORGAN CHASE & CO
$25.94M+79.7%
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND
$20.99M+90.7%
Palo Alto Investors LP
$19.40M0.0%
Nuveen, LLC
$18.67M+25.4%
JACOBS LEVY EQUITY MANAGEMENT, INC
$17.64M-12.6%
Empowered Funds, LLC
$17.49MNew
AQR CAPITAL MANAGEMENT LLC
$16.65M+300.9%
DIMENSIONAL FUND ADVISORS LP
$16.55M+13.7%
D. E. Shaw & Co., Inc.
$15.49M+58.0%
NORTHERN TRUST CORP
$14.74M+10.1%
C WorldWide Group Holding A/S
$14.72M0.0%
GOLDMAN SACHS GROUP INC
$14.60M+29.3%
BAILLIE GIFFORD & CO
$14.42M-11.2%
SILVERCREST ASSET MANAGEMENT GROUP LLC
$14.07M+18.3%
See all 217 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Operating Margin

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/NVCR

Earnings Per Share

13fpro.ai/company/NVCR

Loading ratio trend…

NVCR key financials by period

Reported revenue, net income and operating margin by fiscal year, from NovoCure Ltd's annual filings on SEC EDGAR.

NovoCure Ltd reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$655.4M$-136.2M-23.5%
FY 2024$605.2M$-168.6M-28.2%
FY 2023$509.3M$-207.0M-45.7%
FY 2022$537.8M$-92.5M-16.6%
FY 2021$535.0M$-58.4M-8.3%
FY 2020$494.4M$19.8M6.2%
Source: NVCR filings on SEC EDGAR →

Companies similar to NVCR

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

NVCR insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About NovoCure Ltd (NVCR): stock profile, AI score and financials

NovoCure Ltd (NVCR) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NVCR at 37.4/100 on a composite quality score built from its SEC filings, placing it at rank #2,231 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), NovoCure Ltd reports quarterly revenue of $183.6M, net income of $-15.7M, an operating margin of -5.8%. Top institutional holders of NVCR by reported 13-F value include FMR, BlackRock, Soleus Capital Management, L.P., based on the most recent SEC filings. NVCR trades on the Nasdaq exchange and files with the SEC under CIK 1645113. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NVCR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NovoCure Ltd directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1645113 →